Advisor Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Advisor Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$11K	Hold	186	–	–	﹤0.01%	4322
2019 Q3	$11K	Sell	186 -61	-25%	-$3.43K	﹤0.01%	4304
2019 Q2	$14K	Hold	247	–	–	﹤0.01%	4199
2019 Q1	$12K	Sell	247 -79	-24%	-$3.52K	﹤0.01%	4292
2018 Q4	$13K	Buy	326 +117	+56%	+$6.03K	﹤0.01%	4075
2018 Q3	$14K	Buy	209 +41	+24%	+$3.11K	﹤0.01%	4100
2018 Q2	$13K	Buy	168 +100	+147%	+$6.29K	﹤0.01%	3953
2018 Q1	$4K	Buy	+68	New	+$3.95K	﹤0.01%	4514
2017 Q4	–	Sell	-27	Closed	-$2K	–	5084
2017 Q3	$2K	Sell	27 -273	-91%	-$16.5K	﹤0.01%	4590
2017 Q2	$24K	Hold	300	–	–	﹤0.01%	3394
2017 Q1	$25K	Sell	300 -300	-50%	-$22.3K	﹤0.01%	3235
2016 Q4	$48K	Hold	600	–	–	﹤0.01%	2645
2016 Q3	$42K	Hold	600	–	–	﹤0.01%	2666
2016 Q2	$23K	Buy	+600	New	+$25K	﹤0.01%	2982

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Advisor Group's EGRX Position: Q4 2019 in Review

Advisor Group held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q4 2019 at 186 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #4322.

Advisor Group first reported a position in EGRX in Q2 2016 and has held it in 14 quarters since. The position peaked at $48K in Q4 2016. 176 funds tracked by Wall St. Rank hold EGRX as of Q4 2019.

Advisor Group held 186 shares of Eagle Pharmaceuticals, Inc. worth $11K as of Q4 2019.
Advisor Group left its Eagle Pharmaceuticals, Inc. share count unchanged in Q4 2019.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4322 holding.
Advisor Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and has held it in 14 quarters since.
Advisor Group's Eagle Pharmaceuticals, Inc. position peaked at $48K in Q4 2016.
176 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.